Capital Fund Management S.A. Takes Position in Spark Therapeutics Inc. (ONCE)
Capital Fund Management S.A. bought a new position in shares of Spark Therapeutics Inc. (NASDAQ:ONCE) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 6,800 shares of the company’s stock, valued at approximately $348,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of ONCE. JPMorgan Chase & Co. boosted its position in shares of Spark Therapeutics by 14.6% in the first quarter. JPMorgan Chase & Co. now owns 679,220 shares of the company’s stock worth $20,045,000 after buying an additional 86,659 shares during the last quarter. AXA raised its position in Spark Therapeutics by 52.7% in the first quarter. AXA now owns 247,788 shares of the company’s stock valued at $7,312,000 after buying an additional 85,478 shares during the period. Opus Point Partners Management LLC bought a new position in Spark Therapeutics during the first quarter valued at approximately $930,000. Candriam Luxembourg S.C.A. raised its position in Spark Therapeutics by 80.0% in the second quarter. Candriam Luxembourg S.C.A. now owns 54,000 shares of the company’s stock valued at $2,761,000 after buying an additional 24,000 shares during the period. Finally, American Century Companies Inc. raised its position in Spark Therapeutics by 5.6% in the second quarter. American Century Companies Inc. now owns 394,995 shares of the company’s stock valued at $20,196,000 after buying an additional 20,995 shares during the period. Hedge funds and other institutional investors own 78.79% of the company’s stock.
Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) traded down 2.13% during mid-day trading on Friday, reaching $55.70. The company had a trading volume of 320,184 shares. The company’s 50-day moving average price is $59.77 and its 200-day moving average price is $50.49. Spark Therapeutics Inc. has a 52-week low of $21.20 and a 52-week high of $65.99. The company’s market capitalization is $1.71 billion.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by $0.07. The business earned $1.29 million during the quarter, compared to the consensus estimate of $1.17 million. Spark Therapeutics had a negative return on equity of 26.96% and a negative net margin of 366.76%. The company’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.60) earnings per share. On average, analysts forecast that Spark Therapeutics Inc. will post ($3.96) earnings per share for the current fiscal year.
Several research firms have commented on ONCE. Chardan Capital set a $35.00 price objective on Spark Therapeutics and gave the company a “hold” rating in a research report on Thursday, July 21st. Cantor Fitzgerald reissued a “buy” rating on shares of Spark Therapeutics in a research report on Thursday, July 14th. Wedbush reissued an “underperform” rating and issued a $29.00 price objective (up from $28.00) on shares of Spark Therapeutics in a research report on Wednesday, August 10th. Jefferies Group reissued a “hold” rating on shares of Spark Therapeutics in a research report on Friday, August 5th. Finally, Zacks Investment Research raised Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a research report on Thursday, August 11th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company’s stock. Spark Therapeutics has an average rating of “Hold” and an average target price of $59.50.
In related news, insider Barge Joseph La sold 3,000 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $60.14, for a total value of $180,420.00. Following the completion of the sale, the insider now directly owns 8,325 shares in the company, valued at $500,665.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Katherine A. High sold 500 shares of the company’s stock in a transaction on Monday, August 8th. The stock was sold at an average price of $60.24, for a total transaction of $30,120.00. Following the completion of the sale, the insider now owns 242,290 shares of the company’s stock, valued at $14,595,549.60. The disclosure for this sale can be found here. 9.60% of the stock is currently owned by corporate insiders.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc. (NASDAQ:ONCE).
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.